Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis

Diabetes, Obesity and Metabolism

Volumn 3, Issue 1, 2001, Pages 33-40

  Gentile, S ^a   Turco, S ^a   Guarino, G ^a   Oliviero, B ^a   Annunziata, S ^a   Cozzolino, D ^a   Sasso, F C ^a   Turco, A ^a   Salvatore, T ^a   Torella, R ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Acarbose insulin treatment; Diabetes mellitus; Liver cirrhosis

Indexed keywords

ACARBOSE; AMMONIA; C PEPTIDE; HEMOGLOBIN A1C; INSULIN; PLACEBO;

AMMONIA BLOOD LEVEL; ARTICLE; BACTERIAL GROWTH; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; EVALUATION; FEMALE; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; PERISTALSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STANDARD; STIMULATION; TREATMENT FAILURE;

EID: 0034872965     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00103.x     Document Type: Article

References (36)

1. Der Diabetes mellitus
2. Der Diabetes mellitus
3. Study on the carbohydrate metabolism in chronic infectious hepatitis
4. Liver diseases and diabetes mellitus
5. Glucose tolerance and diabetes mellitus in chronic liver disease
6. Incidence of altered glucose tolerance in liver cirrhosis
7. Liver disease and diabetes mellitus
8. Mechanism of insulin resistance associated with liver cirrhosis: Impact of the aetiology of cirrhosis, the clinical and the nutritional state of the patient
9. Record CO.Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis
10. Alterazioni del metabolismo del glucosio in pazienti con epatopatie
11. Glibenclamide associated reversible cholestasis
12. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled trial
13. Non-insulin-dependent diabetes mellitus and liver cirrhosis
14. 14C-acarbose to rats, dogs and man
15. The effect of the alpha-glucosidase inhibitor Bay G5421 (acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationship in man
16. Subclinical hepatic encephalopathy impairs daily functioning
17. Prospective Diabetes Study (UKPDS): Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with non-insulin-dependent diabetes followed for three years
18. Acarbose in the treatment of type 1 diabetes
19. Classification and diagnosis of diabetes mellitus and other categories of glucose imbalance
20. Survey and portal hypertension
21. Transection of the oesophagus for bleeding oesophageal varices
22. Long-term oral branched-chain amino acid treatment in chronic hepatic enchephalopathy: A randomized double-blind case-controlled trial
23. Effects of spontaneous portal-systemic shunting on insulin metabolism
24. C-peptide and insulin in liver disease
25. Carbohydrate metabolism
26. The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy
27. A double-blind, randomized, placebo controlled study to assess the maximum insulin dose reduction achieved with acrbose in the treatment of insulin-requiring type 2 diabetic patients
28. Safety profile of acarbose, an α-glucosidase inhibitor
29. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: Efficacy and safety of low and high doses
30. Pathophysiology of hepatic encephalopathy
31. Ammonia and GABA-ergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy
32. Hepatic injury caused by acarbose
33. Acarbose-induced acute severe hapatotoxicity
34. Drug-induced hepatotoxicity
35. Aminotransferase activity and acarbose treatment in patients with type 2 diabetes